(S)-2-hydrazinyl-3-phenylpropanoic acid | 1202-31-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-2-hydrazinyl-3-phenylpropanoic acid
• 英文别名: aminophenylalanine；(2S)-2-hydrazinyl-3-phenylpropanoic acid
• CAS: 1202-31-9
• 化学式: C₉H₁₂N₂O₂
• 分子量: 180.206
• InChiKey: KHZVLGLEHBZEPO-QMMMGPOBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.3
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  75.4
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• 海关编码：
  2928000090

反应信息

• 作为反应物：
  描述：

  (S)-2-hydrazinyl-3-phenylpropanoic acid 在 镍 氢气 作用下， 以 水 、 溶剂黄146 为溶剂， 以97%的产率得到L-苯丙氨酸
  参考文献：
  名称：

  Amination of chiral enolates by dialkyl azodiformates. Synthesis of .alpha.-hydrazino acids and .alpha.-amino acids

  摘要：

  DOI：

  10.1021/ja00280a051
• 作为产物：
  描述：

  D-苯丙氨酸 在 2,6-二甲基吡啶 、 盐酸 、 sodium hydroxide 、 硫酸 、 三氟乙酸 、 sodium nitrite 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 氯仿 为溶剂， 反应 30.5h， 生成 (S)-2-hydrazinyl-3-phenylpropanoic acid
  参考文献：
  名称：

  Ribosome-Mediated Incorporation of Hydrazinophenylalanine into Modified Peptide and Protein Analogues

  摘要：

  (S)-alpha-Hydrazinophenylalanyl-tRNA(Phe), an amino acyl-tRNA derivative containing the unnatural amino acid (S)-alpha-hydrazinophenylalanine, was prepared in an effort to examine the stereochemical requirements of the A-site of the ribosome during in vitro protein synthesis. The (S)-alpha-hydrazinophenylalanine moiety was of interest because it contains two nucleophilic centers, the secondary nitrogen attached to Ca, which is normally acylated during the course of peptide bond formation, and the sterically less hindered primary nitrogen. To determine the position of acylation, (S)-alpha-hydrazinophenylalanyl-tRNA(Phe) was tested in an Escherichia coli in vitro protein biosynthesizing system lacking elongation factor G, such that only dipeptide products were formed. The dipeptide product mixture was analyzed by HPLC in direct comparison with authentic synthetic standards. The dipeptide assay utilizing (S)-alpha-hydrazinophenylalanyl-tRNA(Phe) as the A-site tRNA established that the analogue functioned well as an acceptor tRNA; HPLC analysis of the products showed that both dipeptides were formed in approximately equal amounts. When attached to a suppressor tRNA transcript, (S)-alpha-hydrazinophenylalanine was also incorporated into position 27 of dihydrofolate reductase in an E. coli protein synthesizing system by readthrough of a nonsense codon. This finding expands the currently accepted model of peptide bond formation at the ribosome and adds to the repertoire of peptide-like products shown to form at the peptidyltransferase center of the ribosome.

  DOI：

  10.1021/ja974066e

文献信息

• [EN] MITOCHONDRIAL TARGETED RELEASABLE LINKER<br/>[FR] LIEUR LIBÉRABLE À CIBLAGE MITOCHONDRIAL
  申请人：GOVERNING COUNCIL UNIV TORONTO

  公开号：WO2018232491A1

  公开（公告）日：2018-12-27

  There is described herein compound comprising a mitochondrial targeting portion, a cargo portion including a drug unit, and a linker conjugating the mitochondrial targeting portion and the cargo portion, the linker portion cleavable in a mitochondrion of a cell for preferentially releasing the cargo portion within the mitochondrion as compared to a cytoplasm of the cell.

  这里描述了一种化合物，它包括一个线粒体靶向部分、一个包含药物单元的货物部分，以及一个连接线粒体靶向部分和货物部分的连接链，该连接链在细胞的线粒体内可被切割，以便与细胞质相比，优先在线粒体内释放货物部分。
• MODIFIED RELAXIN POLYPEPTIDES AND THEIR USES
  申请人：KRAYNOV Vadim

  公开号：US20120046229A1

  公开（公告）日：2012-02-23

  Modified relaxin polypeptides and their uses thereof are provided

  修改后的弛缓素多肽及其用途
• [EN] MYOGLOBIN-BASED CATALYSTS FOR CARBENE TRANSFER REACTIONS<br/>[FR] CATALYSEURS À BASE DE MYOGLOBINE POUR RÉACTIONS DE TRANSFERT DE CARBÈNE
  申请人：UNIV ROCHESTER

  公开号：WO2016086015A1

  公开（公告）日：2016-06-02

  Methods are provided for carrying out carbene transfer transformations such as olefin cyclopropanation reactions, carbene heteroatom-H insertion reactions (heteroatom = N, S, Si), sigmatropic rearrangement reactions, and aldehyde olefination reactions with high efficiency and selectivity by using a novel class of myoglobin-based biocatalysts. These methods are useful for the synthesis of a variety of organic compounds which contain one or more new carbon-carbon or carbon-heteroatom (N, S, or Si) bond. The methods can be applied for conducting these transformations in vitro (i.e., using the biocatalyst in isolated form) and in vivo (i.e., using the biocatalyst in a whole cell system).

  提供了一种方法来进行碳烯转移反应，如烯烃环丙烷化反应，碳烯杂原子-H插入反应（杂原子= N，S，Si），σ迁移重排反应和醛烯化反应，通过使用一种新型的基于肌红蛋白的生物催化剂，可以高效和选择性地进行。这些方法对于合成含有一个或多个新碳-碳或碳-杂原子（N，S或Si）键的各种有机化合物非常有用。这些方法可以应用于体外（即使用分离形式的生物催化剂）和体内（即在整个细胞系统中使用生物催化剂）进行这些转化。
• [EN] COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES<br/>[FR] COMPOSITIONS CONTENANT DES DÉRIVÉS DE DOLASTATINE LIÉS À DES ACIDES AMINÉS NON NATUREL
  申请人：AMBRX INC

  公开号：WO2012166560A1

  公开（公告）日：2012-12-06

  Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology use.

  披露的是非天然氨基酸和杜洛司他汀类似物，其中包括至少一种非天然氨基酸，以及制造这种非天然氨基酸和多肽的方法。杜洛司他汀类似物可以包括广泛的可能性功能，但通常至少具有一个肟、羰基、二羰基和/或羟基胺基团。还披露了在翻译后进一步修改的非天然氨基酸杜洛司他汀类似物，实施这种修改的方法，以及纯化这种杜洛司他汀类似物的方法。通常，修改后的杜洛司他汀类似物至少包括一个肟、羰基、二羰基和/或羟基胺基团。进一步披露了使用这样的非天然氨基酸杜洛司他汀类似物和修改后的非天然氨基酸杜洛司他汀类似物的方法，包括治疗、诊断和其他生物技术应用。
• Pyrimidine hydantoin analogues which inhibit leukocyte adhesion mediated by VLA-4
  申请人：Konradi W. Andrei

  公开号：US20050261324A1

  公开（公告）日：2005-11-24

  Disclosed are compounds which bind VLA-4 and/or LPAM-1. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4 and/or LPAM-1. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

  披露了与VLA-4和/或LPAM-1结合的化合物。其中某些化合物还能抑制白细胞粘附，尤其是VLA-4和/或LPAM-1介导的白细胞粘附。这类化合物可用于治疗哺乳动物患者，如人类的炎症性疾病，例如哮喘、阿尔茨海默病、动脉粥样硬化、艾滋病痴呆、糖尿病、炎症性肠病、类风湿性关节炎、组织移植、肿瘤转移和心肌缺血。这些化合物也可用于治疗炎症性脑病，如多发性硬化症。